Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone that blocks androgen biosynthesis, is approved for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone or prednisolone 5 mg twice daily. This review evaluates the basis f...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Auchus, Richard J., Yu, Margaret K., Nguyen, Suzanne, Mundle, Suneel D.
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2014
Subjects:
Genitourinary Cancer
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4257741/
https://ncbi.nlm.nih.gov/pubmed/25361624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0167
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items